Compare Flux Power Holdings Inc (FLUX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Novo Nordisk A/S — how do they compare? Flux Power Holdings Inc trades at $0.69 (market cap $15.37M), while Novo Nordisk A/S trades at $51.62 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 14459.3× Flux Power Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | NVO | |
|---|---|---|
Market Cap | $15.37M | $222.24B |
Sector | Utilities | Health |
52-Week High | $6.66 | $71.70 |
52-Week Low | $0.71 | $35.29 |
Enterprise Value | $21.53M | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.701, down 2.18% today, with a bearish technical signal from moving averages. The company reported a net loss of $6.67M in 2025 with revenue of $66.43M, though the price-to-sales ratio remains low at 0.27. Recent news highlights the launch of SkyEMS 3.0 AI software and new executive hires aimed at growth. Analysts are unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -52.27% ROE.
The outlook hinges on execution of growth initiatives amid persistent losses. Opportunities include market expansion in clean energy and software, while risks involve cash flow volatility and competitive pressures. Investors should weigh analyst optimism against fundamental challenges in the evolving energy storage sector.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
